Born from Institut Curie's incubation program, Egle Therapeutics is a biotech company which develops first-in-class immunotherapies targeting suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases. The company is building a proprietary Treg modulating drug portfolio against a large pool of newly unveiled Treg targets.
Year of creation: 2020
Line of business: Biotechnology
Institut Curie: Incubator, institutional co-founder and R&D partner
Egle Therapeutics is leveraging its proprietary translation-based target discovery engine. This engine uses patient samples to map unique transcriptomic signatures and specific targets for Tregs sub-populations. The company is building a proprietary Treg modulating drug portfolio against a large pool of newly unveiled Treg targets. The flagship program pioneers the dis-engagement of tumor-infiltrating Tregs through a unique proprietary series of IL-2 variants that act as IL-2 antagonists.
While the whole competition converges solely on a similar approach to enhance effector T cells by disrupting binding of IL-2 to Tregs, Egle Therapeutics' IL-2 variants conserve intact IL-2 binding to CD25, conferring a unique mechanism of action for starving Treg from endogenous IL-2, while leaving active the CD8+ effector T cell arm of the immune response
Immuno-oncology and autoimmune diseases.
More about Egle Therapeutics:
- Egle Therapeutics enters into a corporate strategic research alliance with Takeda for development of unique immunotherapies